Phase 2 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to give written agreement to take part in the trial.
- You are between 18 and 60 years old (any gender).
- You have been diagnosed with schizophrenia or schizoaffective disorder according to standard diagnostic guidelines (DSM-5).
- You have been taking the same antipsychotic medication for at least 60 days, at a stable dose for more than 1 month, and are able to continue taking it throughout the study.
- Your symptoms score at a certain level on a standard rating scale, including at least one notable "positive" symptom (such as hallucinations or delusions) (confirm with trial site).
- People who have had psychosis for less than 7 years are preferred for this trial.
Who may not be able to join:
- You have used illegal drugs in the last 30 days, or have had a drug dependency in the last 6 months (note: people receiving methadone treatment for opioid withdrawal may still be eligible).
- You have a current or past medical or neurological condition that could cause an unstable health course (people with epilepsy that has been well-controlled on medication for at least 6 months may still be eligible).
- You are pregnant.
- You have a history of immune system disorders, HIV infection, or are currently taking medications that affect the immune system (such as steroids).
- You have previously received or are currently receiving treatment with CGY, or have had an allergic reaction to CGY in the past (confirm with trial site).
- You have an intellectual disability as defined by standard diagnostic guidelines (DSM-5).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Vishwajit L. Nimgaonkar, M.D., Ph.D., University of Pittsburgh
Phone: (412) 246-6353
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improvement in positive symptoms
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.